Genomic Copy Number Gains of ErbB Family Members Predict Poor Clinical Outcomes in Glioma Patients

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Dec 2

PMID 29190914

Citations 5

Authors

Rui Liu

Yiping Qu

Lihong Chen

Jun Pu

Sharui Ma

Xiaozhi Zhang

Qi Yang

Bingyin Shi

Peng Hou

Meiju Ji

Affiliations

Soon will be listed here.

Abstract

The aim of this study was to investigate copy number of ErbB family members (including , , and ) in a cohort of gliomas and benign meningiomas (control subjects), and explore the associations of their copy number with clinicopathological characteristics and clinical outcomes of glioma patients. Using real-time quantitative PCR assay, we demonstrated that copy number of , , and in glioma patients was significantly increased compared to control subjects. Moreover, our data also showed that the risk of cancer-related death was positively associated with copy number gain (CNG) of and , but not . CNG of and was positively related to radiotherapy, while CNG of and was negatively related to chemotherapy. Importantly, CNG significantly shortened median survival times of glioma patients regardless of gender, tumor grade and therapeutic regimens. Stratified analysis showed that CNG of - almost did not influence the survival of male patients, patients with high-grade tumors and patients receiving chemotherapy, but dramatically shortened median survival times of female patients, those with low-grade tumors and those receiving radiotherapy. Collectively, our data not only demonstrate that the members of ErbB family are frequently amplified in gliomas, but also suggest that these common genetic events may be prognostic factors for poor clinical outcomes in glioma patients.

Citing Articles

Isoliquiritigenin inhibits circ0030018 to suppress glioma tumorigenesis via the miR-1236/HER2 signaling pathway.

Liu A, Jiang B, Song C, Zhong Q, Mo Y, Yang R MedComm (2020). 2023; 4(3):e282.

PMID: 37250146 PMC: 10220153. DOI: 10.1002/mco2.282.

The peculiar challenge of bringing CAR-T cells into the brain: Perspectives in the clinical application to the treatment of pediatric central nervous system tumors.

Del Baldo G, Del Bufalo F, Pinacchio C, Carai A, Quintarelli C, De Angelis B Front Immunol. 2023; 14:1142597.

PMID: 37025994 PMC: 10072260. DOI: 10.3389/fimmu.2023.1142597.

Somatic copy number alterations are predictive of progression-free survival in patients with lung adenocarcinoma undergoing radiotherapy.

Kou F, Wu L, Guo Y, Zhang B, Li B, Huang Z Cancer Biol Med. 2021; .

PMID: 34448554 PMC: 9196051. DOI: 10.20892/j.issn.2095-3941.2020.0728.

CAR T cells for brain tumors: Lessons learned and road ahead.

Akhavan D, Alizadeh D, Wang D, Weist M, Shepphird J, Brown C Immunol Rev. 2019; 290(1):60-84.

PMID: 31355493 PMC: 6771592. DOI: 10.1111/imr.12773.

Downregulation of microRNA-374a predicts poor prognosis in human glioma.

Dong Q, Yuan G, Liu M, Xie Q, Hu J, Wang M Exp Ther Med. 2019; 17(3):2077-2084.

PMID: 30867694 PMC: 6395951. DOI: 10.3892/etm.2019.7190.

References

Mares J, Polanska V, Gorgens H, Sedlacek Z, Marikova T, Bocek P . Oncogene amplification and expression in pediatric solid tumors. Neoplasma. 1998; 45(3):123-7. View

Soria J, Cortes J, Massard C, Armand J, De Andreis D, Ropert S . Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors. Ann Oncol. 2011; 23(2):463-71. DOI: 10.1093/annonc/mdr137. View

Wong T, Lee F, Yu C, Luo F, Oppenheimer S, Zhang H . Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling. Clin Cancer Res. 2006; 12(20 Pt 1):6186-93. DOI: 10.1158/1078-0432.CCR-06-0642. View

Rajesh Y, Pal I, Banik P, Chakraborty S, Borkar S, Dey G . Insights into molecular therapy of glioma: current challenges and next generation blueprint. Acta Pharmacol Sin. 2017; 38(5):591-613. PMC: 5457688. DOI: 10.1038/aps.2016.167. View

Chen R, Smith-Cohn M, Cohen A, Colman H . Glioma Subclassifications and Their Clinical Significance. Neurotherapeutics. 2017; 14(2):284-297. PMC: 5398991. DOI: 10.1007/s13311-017-0519-x. View

Wilson K, Gilmore J, Foley J, Lemmon M, Riese 2nd D . Functional selectivity of EGF family peptide growth factors: implications for cancer. Pharmacol Ther. 2009; 122(1):1-8. PMC: 2665203. DOI: 10.1016/j.pharmthera.2008.11.008. View

Hou P, Liu D, Shan Y, Hu S, Studeman K, Condouris S . Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res. 2007; 13(4):1161-70. DOI: 10.1158/1078-0432.CCR-06-1125. View

Yao T, Zhang J, Prados M, Weiss W, James C, Nicolaides T . EGFR blockade prevents glioma escape from BRAFV600E targeted therapy. Oncotarget. 2015; 6(26):21993-2005. PMC: 4673141. DOI: 10.18632/oncotarget.4014. View

Gupta A, McKenna W, Weber C, Feldman M, Goldsmith J, Mick R . Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res. 2002; 8(3):885-92. View

10.

Shi J, Qu Y, Li X, Sui F, Yao D, Yang Q . Increased expression of EHF via gene amplification contributes to the activation of HER family signaling and associates with poor survival in gastric cancer. Cell Death Dis. 2016; 7(10):e2442. PMC: 5134001. DOI: 10.1038/cddis.2016.346. View

11.

Chang L, Graham P, Hao J, Ni J, Bucci J, Cozzi P . Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance. Cell Death Dis. 2013; 4:e875. PMC: 3920940. DOI: 10.1038/cddis.2013.407. View

12.

Ohgaki H . Epidemiology of brain tumors. Methods Mol Biol. 2008; 472:323-42. DOI: 10.1007/978-1-60327-492-0_14. View

13.

Shi J, Yao D, Liu W, Wang N, Lv H, He N . Frequent gene amplification predicts poor prognosis in gastric cancer. Int J Mol Sci. 2012; 13(4):4714-4726. PMC: 3344242. DOI: 10.3390/ijms13044714. View

14.

Gurtner K, Ebert N, Pfitzmann D, Eicheler W, Zips D, Baumann M . Effect of combined irradiation and EGFR/Erb-B inhibition with BIBW 2992 on proliferation and tumour cure in cell lines and xenografts. Radiat Oncol. 2014; 9:261. PMC: 4271482. DOI: 10.1186/s13014-014-0261-z. View

15.

Andersson U, Schwartzbaum J, Wiklund F, Sjostrom S, Liu Y, Tsavachidis S . A comprehensive study of the association between the EGFR and ERBB2 genes and glioma risk. Acta Oncol. 2010; 49(6):767-75. DOI: 10.3109/0284186X.2010.480980. View

16.

Kwon M, Kim S, Kwon M, Kong D, Lee D, Park S . Mutated IDH1 is a favorable prognostic factor for type 2 gliomatosis cerebri. Brain Pathol. 2011; 22(3):307-17. PMC: 8092965. DOI: 10.1111/j.1750-3639.2011.00532.x. View

17.

Andersson U, Guo D, Malmer B, Bergenheim A, Brannstrom T, Hedman H . Epidermal growth factor receptor family (EGFR, ErbB2-4) in gliomas and meningiomas. Acta Neuropathol. 2004; 108(2):135-42. DOI: 10.1007/s00401-004-0875-6. View

18.

Brat D, Verhaak R, Aldape K, Yung W, Salama S, Cooper L . Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med. 2015; 372(26):2481-98. PMC: 4530011. DOI: 10.1056/NEJMoa1402121. View

19.

Ji M, Guan H, Gao C, Shi B, Hou P . Highly frequent promoter methylation and PIK3CA amplification in non-small cell lung cancer (NSCLC). BMC Cancer. 2011; 11:147. PMC: 3098185. DOI: 10.1186/1471-2407-11-147. View

20.

Yang H, Liu M, Zhou B, Deng Y, He N, Jiang H . Chemiluminescent Detection for Estimating Relative Copy Numbers of Porcine Endogenous Retrovirus Proviruses from Chinese Minipigs Based on Magnetic Nanoparticles. J Nanosci Nanotechnol. 2016; 16(6):6505-10. DOI: 10.1166/jnn.2016.10841. View